Zelira Therapeutics (ASX:ZLD) Other Current Liabilities: A$0.00 Mil (As of Jun. 2025)


What is Zelira Therapeutics Other Current Liabilities?

Zelira Therapeutics ASX:ZLD Other Current Liabilities is A$0.00 Mil as of Jun. 2025. The stock has 7 warning signs investors should review.

Zelira Therapeutics's other current liabilities for the quarter that ended in Jun. 2025 was A$0.00 Mil.

Zelira Therapeutics's quarterly other current liabilities declined from Jun. 2024 (A$0.00 Mil) to Dec. 2024 (A$-0.00 Mil) but then increased from Dec. 2024 (A$-0.00 Mil) to Jun. 2025 (A$0.00 Mil).

Zelira Therapeutics's annual other current liabilities increased from Jun. 2023 (A$-0.00 Mil) to Jun. 2024 (A$0.00 Mil) but then stayed the same from Jun. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.00 Mil).

Zelira Therapeutics Other Current Liabilities Related Terms

Zelira Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics Other Current Liabilities Chart

Zelira Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.00 0.00 0.00

Zelira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 -0.00 0.00

Zelira Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of A$0.00 Mil mean?
Zelira Therapeutics (ASX:ZLD) has a Other Current Liabilities of A$0.00 Mil as of Jun. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Zelira Therapeutics.
Is Zelira Therapeutics' Other Current Liabilities too high?
Zelira Therapeutics' current Other Current Liabilities is A$0.00 Mil.
How does Zelira Therapeutics' Other Current Liabilities compare to MTNB and SXTP?
Zelira Therapeutics' Other Current Liabilities of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Zelira Therapeutics. Zelira Therapeutics's current Other Current Liabilities is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ASX:ZLD) has a current Other Current Liabilities of A$0.00 Mil. The stock's GF Value™ is A$0.12, compared to a current price of A$0.50 — trading 316.7% above its estimated fair value. The current Other Current Liabilities is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Zelira Therapeutics (ASX:ZLD), the current Other Current Liabilities is A$0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelira Therapeutics Business Description

Other Exchanges ZLDAF:USA
Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.